🔎 Trials Near Me

ホーム › HIV › メリーランド州

メリーランド州におけるHIVの臨床試験

メリーランド州内の拠点で、HIVに関する29件の研究が参加者を募集しています。

メリーランド州内の都市

公式研究テキスト(英語)

Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption

  • National Institutes of Health Clinical Center, Bethesda
被験者募集中第2相
18歳〜100歳 · 全性別 · 2026/10/02更新 · NCT05419024

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

  • Chase Brexton Health Care, Baltimore
被験者募集中観察研究
18歳以上 · 全性別 · 2026/10/01更新 · NCT07473778

Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease

  • National Institutes of Health Clinical Center, Bethesda
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/28更新 · NCT03300830

Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants

  • National Institutes of Health Clinical Center, Bethesda
被験者募集中観察研究
18歳〜120歳 · 全性別 · 2026/09/28更新 · NCT00039689

Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer

  • National Institutes of Health Clinical Center, Bethesda
被験者募集中観察研究
18歳〜120歳 · 全性別 · 2026/09/28更新 · NCT00006518

Viral Load in Blood and Lymph Tissues in People Living With HIV

  • National Institutes of Health Clinical Center, Bethesda
被験者募集中観察研究健康なボランティア歓迎
18歳〜100歳 · 全性別 · 2026/09/28更新 · NCT00001316

A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

  • GSK Investigational Site, Baltimore
被験者募集中第3相
12歳以上 · 全性別 · 2026/09/28更新 · NCT07650916

Leukapheresis to Obtain Plasma or Lymphocytes for Studies of HIV-infected Patients, Including Long-term Non-progressors

  • National Institutes of Health Clinical Center, Bethesda
被験者募集中観察研究
18歳〜100歳 · 全性別 · 2026/09/22更新 · NCT00029445

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

  • National Institutes of Health Clinical Center, Bethesda
被験者募集中第1/2相健康なボランティア歓迎
12歳〜120歳 · 全性別 · 2026/09/22更新 · NCT05470491

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

  • National Institutes of Health Clinical Center, Bethesda
被験者募集中第1相
18歳〜99歳 · 全性別 · 2026/09/17更新 · NCT04902443

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

  • 5092, Johns Hopkins Clinical Research Site, Baltimore
被験者募集中第1/2相
48 Hours · 全性別 · 2026/09/09更新 · NCT02140255

Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)

  • National Institutes of Health Clinical Center, Bethesda
被験者募集中観察研究健康なボランティア歓迎
2歳〜120歳 · 全性別 · 2026/08/31更新 · NCT01730131

Clinical and Immunologic Monitoring of Patients With Known or Suspected HIV Infection

  • National Institutes of Health Clinical Center, Bethesda
被験者募集中観察研究
18歳以上 · 全性別 · 2026/08/27更新 · NCT00789009

Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma

  • National Institutes of Health Clinical Center, Bethesda
被験者募集中第1/2相
18歳〜99歳 · 全性別 · 2026/08/25更新 · NCT04941274

PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma

  • National Institutes of Health Clinical Center, Bethesda
被験者募集中第1/2相
18歳〜99歳 · 全性別 · 2026/08/24更新 · NCT04303117

Expanding HOPE Liver

  • Johns Hopkins University (Site #: 71119), Baltimore
被験者募集中観察研究
18歳以上 · 全性別 · 2026/08/21更新 · NCT07778459

Screen2Prevent (S2P)

  • Johns Hopkins University, Baltimore
被験者募集中健康なボランティア歓迎
14歳〜24歳 · 全性別 · 2026/08/17更新 · NCT07728123

A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

  • Johns Hopkins University, Baltimore
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/30更新 · NCT07143968

A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants

  • GSK Investigational Site, Baltimore
被験者募集中第1相健康なボランティア歓迎
18歳〜55歳 · 全性別 · 2026/07/13更新 · NCT07525544

Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy

  • National Institutes of Health Clinical Center, Bethesda
被験者募集中第1相
18歳〜75歳 · 全性別 · 2026/07/08更新 · NCT06819176

Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)

  • Johns Hopkins University, Baltimore
被験者募集中
18歳以上 · 全性別 · 2026/06/22更新 · NCT06263426

Skeletal Muscle Energetics and Fatiguability in Older Individuals

  • Johns Hopkins Hospital, Baltimore
被験者募集中観察研究健康なボランティア歓迎
60歳〜90歳 · 全性別 · 2026/06/08更新 · NCT04142047

Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
被験者募集中観察研究
18歳以上 · 全性別 · 2026/06/01更新 · NCT05663502

A Setting Focus Overdose Prevention Intervention

  • Lighthouse Studies at Peer Point, Baltimore
被験者募集中健康なボランティア歓迎
18歳以上 · 全性別 · 2026/05/22更新 · NCT05320835

Menopausal HT for Women Living With HIV (HoT)

  • 201 Johns Hopkins University CRS, Baltimore
被験者募集中第4相
40歳〜60歳 · 女性 · 2026/05/22更新 · NCT06856174

The Collaborative Care PrTNER Study

  • Johns Hopkins Center for Adolescent and Young Adult Health, Baltimore
被験者募集中健康なボランティア歓迎
15歳〜29歳 · 男性 · 2026/05/18更新 · NCT06585631

Strategies to AchieVe Viral Suppression for Youth With HIV

  • Johns Hopkins University, Baltimore
被験者募集中
12歳〜30歳 · 全性別 · 2026/02/04更新 · NCT06886971

Syringe Service Based Telemedicine and Social Network Driven HIV Prevention Service Implementation

  • Johns Hopkins Hospital, Baltimore
  • Frederick County Health Department, Street Safe Program, Frederick
被験者募集中
18歳以上 · 全性別 · 2025/11/10更新 · NCT06103370

Peer Behavioral Activation Utilization to Improve Substance Use and HIV Outcomes in People Receiving Long Acting Injectable-PrEP/ART (PUSH)

  • Baltimore Safe Haven, Baltimore
被験者募集中健康なボランティア歓迎
18歳〜88歳 · 全性別 · 2025/10/31更新 · NCT06501781

ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。